Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview

Author(s): Kerasia-Maria Plachouri*, Eleftheria Vryzaki and Sophia Georgiou

Volume 14, Issue 1, 2019

Page: [14 - 20] Pages: 7

DOI: 10.2174/1574886313666180730114309

Price: $65

Abstract

Background: The introduction of Immune Checkpoint Inhibitors in the recent years has resulted in high response rates and extended survival in patients with metastatic/advanced malignancies. Their mechanism of action is the indirect activation of cytotoxic T-cells through the blockade of inhibitory receptors of immunomodulatory pathways, such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1) and its ligand (PD-L1). Despite their impressive therapeutic results, they can also induce immune-related toxicity, affecting various organs, including the skin.

Objective: To provide an updated summarized overview of the most common immune-mediated cutaneous side effects and their management.

Method: English articles derived from the databases PubMed and SCOPUS and published between 2009 and 2018, were analyzed for this narrative review.

Results: The most common adverse cutaneous reactions include maculopapular rash, lichenoid reactions, vitiligo and pruritus, with severity Grade 1 or 2. Less frequent but eventually life-threatening skin side effects, including Stevens-Johnson syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Toxic Epidermal necrolysis, have also been reported.

Conclusion: Basic knowledge of the Immune-Checkpoint-Inhibitors-induced skin toxicity is necessary in order to recognize these treatment-related complications. The most frequent skin side effects, such as maculopapular rash, vitiligo and pruritus, tend to subside under symptomatic treatment so that permanent discontinuation of therapy is not commonly necessary. In the case of life-threatening side effects, apart from the necessary symptomatic treatment, the immunotherapy should be permanently stopped. Information concerning the management of ICIs-mediated skin toxicity can be obtained from the literature as well as from the Summary of Product Characteristics of each agent.

Keywords: Cutaneous adverse reactions, immune checkpoint inhibitors, management, melanoma, skin toxicity, therapy.

« Previous Next »
Graphical Abstract

[1]
Dadu R, Zobniw CH, Diab A. Managing adverse events with immune checkpoint agents. Cancer J 2016; 22(2): 121-9.
[2]
Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer 2016; 54: 139-48.
[3]
Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12-25.
[4]
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy. Am J Clin Dermatol 2018; 19(3): 345-61.
[5]
Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: The underlying mechanisms and clinical management. Scientifica 2013; 13: 1-19.
[6]
Collins LK, Chapman MS, Carter JB, et al. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 2017; 41(2): 125-8.
[7]
Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports. PLoS One 2016; 11(7): 1-5.
[8]
Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26: 2375-91.
[9]
Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. Transl Lung Cancer Res 2015; 4(5): 560-75.
[10]
Habre M, Habre SB, Kourie HR. Dermatologic adverse events of checkpoint inhibitors: What an oncologist should know. Immunotherapy 2016; 8(12): 1437-46.
[11]
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6: e1000097.
[12]
Tetzlaff MT, Nagarajan P, Chon S, et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: A detailed examination of the clinicopathologic features. Am J Dermatopathol 2017; 39(2): 121-9.
[13]
Postow M, Wolchok J. Toxicities associated with checkpoint inhibitor immunotherapy. Up to Date [updated 2018 May 24; cited 2018 May 30]. Available from https://www.uptodate.com/contents/toxicities-associated-with-checkpoint-inhibitor-immunotherapy
[14]
Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016; 45: 7-18.
[15]
Abdel-Rahman O, El Halawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: A meta-analysis. Future Oncol 2015; 11: 2471-84.
[16]
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34.
[17]
Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-32.
[18]
Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908-18.
[19]
Kahler KC, Hassel JC, Heinzerling L, et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges 2016; 14(7): 662-81.
[20]
Goldinger SM, Stieger P, Meier B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res 2016; 22(16): 4023-9.
[21]
Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of Anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016; 28(4): 254-63.
[22]
Lacouture ME, Wolchok JD, Yosipovitch G, Kaehler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014; 71: 161-9.
[23]
Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis. BMC Med 2015; 13: 211.
[24]
Hwang SJE, Anforth R, Carlos G, et al. Cutaneous adverse events of new anti-melanoma therapies: Classification and management. Actas Dermo-Sifiliograf 2017; 108(1): 6-16.
[25]
Saw S, Lee HY, Ng SQ. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. European J of Cancer (EJC) 2017; 81: 237-9.
[26]
Pathria M, Mundi J, Trufant J. A case of Stevens-Johnson syndrome in a patient on ipilimumab. Int J Case Rep Imag 2016; 7(5): 300-2.
[27]
Nayar N, Briscoe K, Penas F. Toxic epidermal Necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory. Metastatic Melanoma. J Immunother 2016; 39(3): 149-52.
[28]
Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol 2017; 44(4): 381-4.
[29]
Rabionet A, Vivar KL, Deschaine M, et al. Toxic epidermal necrolysis cutaneous eruption associated with Anti-PD-1 antibody therapy. Eposter. [cited 2018 Mar 16]. Available from https://www.eposters.net/poster/toxic-epidermal-necrolysis-cutaneous-eruption-associated-with-anti-pd-1-antibody-therapy
[30]
Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol 2017; 44: 381-4.
[31]
Lo Ja. Fisher DE, Flaherty Kt. Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol 2015; 1(9): 1340-1.
[32]
Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016; 152: 45-51.
[33]
Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 190-209.
[34]
De Golian E, Kwong BY, Swetter SM, Pugliese SB. Cutaneous complications of targeted melanoma therapy. Curr Treat Options Oncol 2016; 17(11): 57.
[35]
Shi VJ, Rodic N, Gettinger S, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 2016; 152: 1128-36.
[36]
Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer 2017; 25: 1713-39.
[37]
National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS. May 29, 2009. NIH Publication # 09-7473.
[38]
Ito J, Fujimoto D, Nakamura A, et al. Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer 2017; 109: 58-61.
[39]
Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33(28): 3193-8.
[40]
Yervoy®, INN-Ipilimumab Summary of Product Characteristics [cited 2018 July 19]. Available from https://ec.europa.eu/ health/documents/community-register/2016/20160421134557/anx_134557_en.pdf
[41]
Keytruda®, INN-Pembrolizumab Summay of Product Characteristics [cited 2018 July 19]. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003820/WC500190990.pdf
[42]
Opdivo®, INN-Nivolumab Summary of Product Characteristics [cited 2018 July 19]. Available from http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR_-_Product_Information/ human/003985/WC500189765.pdf
[43]
Pappas-Taffer L, Rosenbach M, Chu E. The cutaneous side effects of selective BRAF inhibitors and anti-CTLA4 agents: The growing role of the dermatologist in the management of patients with metastatic melanoma. Curr Dermatol Rep 2013; 2: 84-100.
[44]
Hwang SJ, Carlos G, Walkade D, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. J Am Acad Dermatol 2016; 74(3): 455-61.
[45]
Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: An analysis of rare side effects of Anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8(1): e53745.
[46]
Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, et al. Erythema-nodosum panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy. Report of two patients. J Cutan Pathol 2017; 44(12): 1080-6.
[47]
Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: A report on bullous skin eruptions. J Cutan Pathol 2016; 43: 688-96.
[48]
Page B, Borradori L, Beltraminelli H, Yawalkar N, Hunger RE. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab. J Eur Acad Dermatol Venereol 2018; 32(7): e256-7.
[49]
Bousquet E, Zarbo A, Tournier E, et al. Development of papulopustular rosacea during nivolumab therapy for metastatic cancer. Acta Derm Venereol 2017; 97: 539-40.
[50]
Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 2009; 218(1): 69-70.
[51]
Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017; 76: 43-50.
[52]
Zarbo A, Belum VR, Sibaud V, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol 2017; 176: 1649-52.
[53]
Bischoff J. Checkpoint inhibitors in breast cancer - current status and future directions. Breast Care 2018; 13: 27-31.
[54]
Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 210-25.
[55]
Beck KM, Dong J, Geskin LJ, et al. Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid. J Immunother Cancer 2016; 4: 20.
[56]
Chia PL, John T. Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC). J Immunother 2016; 39: 202-4.
[57]
Munoz J, Guillot B, Girard C, Dereure O, Du-Thanh A. First report of ipilimumab-induced Grover disease. Br J Dermatol 2014; 171: 1236-7.
[58]
Sheik S, Goddard AL, Luke JJ, et al. Drug-induced dermatomyositis following ipilimumab therapy. JAMA Dermatol 2015; 151: 195-9.
[59]
Cotliar J, Querfeld C, Boswell WJ, Raja N, Raz D, Chen R. Pembrolizumab-associated sarcoidosis. JAAD Case Rep 2016; 2: 290-3.
[60]
Suozzi KC, Stahl M, Ko CJ, et al. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep 2016; 2: 264-8.

Rights & Permissions Print Cite
Article Metrics
237
27
1
1
© 2024 Bentham Science Publishers | Privacy Policy